Stonepine Capital Management, LLC Cidara Therapeutics, Inc. Transaction History

Stonepine Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.75 - $1.98 $750 - $1,980	1,000 New	1,000 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.43 - $0.91 $983,873 - $2.08 Million	-2,288,077 Reduced 91.65%	208,443 $102,000
Q1 2022 May 16, 2022	BUY	$0.67 - $1.39 $123,943 - $257,136	184,990 Added 8.0%	2,496,520 $2.08 Million
Q4 2021 Feb 14, 2022	BUY	$1.18 - $2.18 $1.8 Million - $3.33 Million	1,528,713 Added 195.28%	2,311,530 $2.94 Million
Q3 2021 Nov 12, 2021	SELL	$1.48 - $2.35 $634,134 - $1.01 Million	-428,469 Reduced 35.37%	782,817 $1.75 Million
Q2 2021 Aug 16, 2021	BUY	$1.87 - $2.7 $2.27 Million - $3.27 Million	1,211,286 New	1,211,286 $2.45 Million
Q2 2020 Aug 13, 2020	SELL	$2.39 - $4.0 $3.11 Million - $5.21 Million	-1,302,981 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$1.74 - $4.26 $2.27 Million - $5.55 Million	1,302,981 New	1,302,981 $3.23 Million
Q4 2018 Feb 13, 2019	SELL	$2.1 - $4.5 $1.38 Million - $2.95 Million	-656,148 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$3.7 - $5.25 $853,282 - $1.21 Million	230,617 Added 54.2%	656,148 $2.89 Million
Q2 2018 Aug 14, 2018	BUY	$3.75 - $6.05 $1.6 Million - $2.57 Million	425,531 New	425,531 $2.21 Million

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.63B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stonepine Capital Management, LLC with notifications on news.